Table 2.
Antiangiogenetic therapies in cervical cancer
| Study | Treatment | Pts | Pathology | RR (%) | P-value | PFS (w) | HR | P-value | OS (ms) | HR | P-value | Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monk et al105 | Pazopanib + lapatinib | 78 | SCC-ADC | na | na | na | na | na | na | na | na | II |
| Pazopanib | 74 | 9 | na | 18.1 | 0.66 | 0.013 | 50.7 | 0.67 | 0.045 | |||
| Lapatinib | 78 | 5 | na | 17.1 | 0.66 | 0.013 | 39.1 | 0.67 | 0.045 | |||
| Mackay et al103 | Sunitinib | 19 | SCC-ADC | 0 | na | 3.5 | na | na | na | na | na | II |
| Candelaria et al115 | Imatinib mesylate | 12 | SCC-ADC | 0 | na | 1.93 | na | na | 5.1 | na | na | Pilot |
Abbreviations: Pts, patients; w, weeks; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ms, months; RR, response rate; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; na, not available.